David Moatazedi Sells 10,539 Shares of Evolus (NASDAQ:EOLS) Stock

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 10,539 shares of the firm’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares in the company, valued at $2,533,874.20. The trade was a 2.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Evolus Stock Performance

Evolus stock opened at $6.67 on Wednesday. Evolus, Inc. has a one year low of $5.71 and a one year high of $17.12. The company has a 50-day simple moving average of $6.91 and a 200-day simple moving average of $7.46. The firm has a market capitalization of $432.35 million, a P/E ratio of -7.25 and a beta of 0.87.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. Evolus had a negative net margin of 20.49% and a negative return on equity of 759.04%. The firm had revenue of $68.97 million for the quarter, compared to the consensus estimate of $91.23 million. As a group, sell-side analysts forecast that Evolus, Inc. will post -0.61 earnings per share for the current year.

Institutional Investors Weigh In On Evolus

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Rice Hall James & Associates LLC lifted its holdings in shares of Evolus by 17.4% during the third quarter. Rice Hall James & Associates LLC now owns 1,168,886 shares of the company’s stock valued at $7,177,000 after purchasing an additional 172,846 shares during the last quarter. Pinnacle Associates Ltd. purchased a new stake in Evolus during the second quarter valued at about $6,318,000. PDT Partners LLC acquired a new position in shares of Evolus in the first quarter worth about $730,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Evolus in the second quarter worth approximately $22,431,000. Finally, Frontier Capital Management Co. LLC raised its holdings in shares of Evolus by 37.9% during the second quarter. Frontier Capital Management Co. LLC now owns 1,664,828 shares of the company’s stock valued at $15,333,000 after acquiring an additional 457,533 shares during the period. 90.69% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

EOLS has been the topic of several recent analyst reports. BTIG Research reaffirmed a “buy” rating and set a $18.00 target price on shares of Evolus in a research note on Monday, September 8th. Needham & Company LLC restated a “hold” rating on shares of Evolus in a research note on Wednesday, December 24th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Mizuho reduced their price target on shares of Evolus from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Monday, December 1st. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.